ESPR - Esperion Therapeutics, Inc.
| Previous Close | 36.78 |
| Open | 36.92 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 36.35 - 37.44 |
| 52 Week Range | 33.13 - 60.99 |
| Volume | 191,127 |
| Avg. Volume | 444,959 |
| Market Cap | 1.001B |
| Beta (3Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.86 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.38 |
- InvestorPlace
7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying
Insider buying could be a bullish signal for a stock. When an insider of a company wants to buy or sell their company's stock, they need to inform the U.S. Securities and Exchange Commission. An insider is a person who has access to confidential information about a company. In other words, the important people in a company need to tell the public if they are buying or selling their company's stock.I always like to know what the insiders are doing when I consider making an investment. Even more so, I like to see if they are buying after the price has dropped dramatically. A lack of insider buying could suggest that the selloff was justified, while meaningful buying could be a significant bullish signal. * 7 Stocks to Buy In a Flat Market There are many reasons why an insider of a company may decide to sell. They may need money tuition or to buy a new house. But there is only one reason why an insider would buy their company's stock. They believe it is undervalued and eventually they will make money.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThere has been significant buying by the insiders in the following micro-cap and small-cap stocks recently. Ideanomics (IDEX)Ideanomics Inc. (NASDAQ:IDEX) is a fintech company with significant operations in the Chinese electric vehicle market. It is currently trading with a valuation of around $200 million.Like many companies with exposure to China, IDEX has seen the price of its stock decline over the past year. However, it does seem to be coming back. Despite the recent volatility it is up 27% year-to-date. This company seems to have a lot going for it. Many analysts expect the Chinese EV market to expand rapidly over the next few year which would benefit IDEX.Additionally, in the most recent quarter the company reported earnings of 5 cents a share. This is a significant improvement over last year's loss of 12 cents in the same quarter. This could be a signal that Alfred Poor, who became the CEO a year ago, has begun to turn things around.Bruno Zheng Wu is the chairman of the company. He recently acquired a block of stock in a private transaction. The seller was having liquidity concerns due to issues with other investments, so Wu agreed to pay $3 a share for 1.7 million shares. This was a personal investment of over $5 million and could be a significant bullish signal. Briggs & Stratton (BGG)Briggs & Stratton (NYSE:BGG) designs, manufactures and sells gasoline engines and outdoor power equipment. After its recent price drop, the company has a market cap of $187 million. Most analysts would consider this to be a micro-cap stock.BGG stock dropped by almost 50% when it reported earnings which were way short of estimates. The company lost 45 cents a share while estimates called for a 45 cent profit. It traded at a multi-decade low but has since recovered a little.Some of the insiders must think that this selloff was an overreaction and that the stock is a good value at these levels. There has been significant insider buying. * 7 Deeply Discounted Energy Stocks to Buy Frank Jaehnert is a director of BGG. He just bought 40,000 shares at $4.39. This was a $175,600 investment. Vice President of Product Innovation Mike Zeiler just paid $4.25 for 43,000 shares. This was an investment of $180,000. Other insiders have recently purchased the stock as well. Esperion Therapeutics (ESPR)Esperion Therapeutics (NASDAQ:ESPR) operates as a clinical stage bio-pharmaceutical company. The current market cap is about $1 billion.ESPR stock has trended lower since June when it was trading around $52. Now it is around $35.This could be because the company continues to lose money. In early August it reported an earnings loss of $2.01 per share. Analysts were looking for a loss of around $1.85 per share.Tim Mayleben is the president and CEO of the company. He must think that the sellers have over-reacted to the news because he is buying the stock. He just made a substantial investment of $260,000 when he purchased 7,500 shares at an average price $34.55 on Sept. 6.Wall Street agrees with Mayleben that the stock is a good value at current levels. Twelve firms follow Esperion. Nine of them have "buy" ratings on it while there are two "holds" and one "sell." The average target price is around $85, significantly higher than current levels. Forterra (FRTA)Forterra (NASDAQ:FRTA) manufactures and sells pipe and precast products. At current levels the market valuation is around $402 million.FRTA stock has been on a roller coaster ride over the past year. After trading around $9 last August, it lost almost two-thirds of its value when it traded as low as $3.45 in December. Since then it has been very volatile, but it is slowly recovering and currently trading around $6 a share.Karl Watson is the CEO of Forterra. He is betting that this rally will continue. He just paid $5.98 for 20,000 shares. Back on Aug. 9, he made an even larger investment. He put $450,000 into the stock when he bought 65,200 shares at an average price of $6.94. * 7 Best Tech Stocks to Buy Right Now Other insiders have been buyers of the stock as well. Clinton McDonough is a director of Forterra. He recently bought 10,000 shares at $6.84. President of the Water & Pipes Products Divisions Vikrant Bhatia also made a substantial investment when bought 17,175 shares at $6.56 per share in August. Sally Beauty (SBH)Sally Beauty (NYSE:SBH) is an international retailer and distributor of professional beauty supplies. SBH stock's current market cap is around $1.6 billion.SBH has been trending lower since April. Now shares are in the $13 range. Some analysts believe that this is due to shareholders' concern about the trade war and predictions of a recession.This is in spite of the fact that it has solid earnings and at current levels has a very low forward price-to-earnings ratio of 6.John Miller is a director of the company. Apparently he thinks the stock will soon rally because he just made a $500,000 investment. He paid $12.21 for 40,500 shares. Marshall Eisenberg recently paid $11.89 for 10,000 shares. He is also a director of Sally Beauty. Harvest Capital Credit (HCAP)Harvest Capital Credit (NASDAQ:HCAP) is an externally managed closed-end investment company. This is a micro-cap company with a current market value of around $62 million.HCAP has been trending lower since reporting earnings and revenue that each fell short of expectations. Since then it has dropped by about 10%.CEO of Harvest Capital Credit Joe Jolson has made numerous investments in the stock. The most recently reported one was on Sept. 6. He made a $150,000 investment when he paid an average price of $9.77 for 15,100 shares. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off In addition to this, over the prior few weeks he also bought about a total of 15,000 shares. It could be that he is attracted to the current dividend at these levels, which is almost 10%. Gulf Resources (GURE)Gulf Resources (NASDAQ:GURE) manufactures chemical products. At current levels it has a market valuation of about $34 million, making it a micro-cap company.Like many other companies in this sector, Gulf has been facing some challenges. This stock has lost about half of its value since April when it was trading around $1.41. The most recent close was 76 cents.As a penny stock company that is based in China, this company is probably an extremely risky investment. Remember, penny stocks are penny stocks for a reason.Ming Yang is a director of Gulf Resources. He must believe that despite the risk, it may be a good investment at current levels. He invested almost $500,000 into the stock when he bought over 660,000 shares at 72 cents.At the time of this writing, Mark Putrino did not have any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 3 Artificial Intelligence Stocks to Buy * 7 Industrial Stocks to Buy for a Strong U.S. Economy * 3 Beaten-Down Bank Stocks to Buy and Hold for the Long Term The post 7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying appeared first on InvestorPlace.
- Zacks
Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com
Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares
President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 7,500 shares of ESPR on 09/06/2019 at an average price of $34.55 a share. Continue reading...
- GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 30, 2019 -- Esperion (NASDAQ: ESPR) today announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted.
- Zacks
Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
- GlobeNewswire
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control.
- Zacks
Esperion's Drugs in Review Hold Potential, Funds a Concern
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.
- Simply Wall St.
Does Market Volatility Impact Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Share Price?
If you own shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR) then it's worth thinking about how it contributes to...
- Zacks
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
- Zacks
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -8.06% and 5.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
ANN ARBOR, Mich., Aug. 08, 2019 -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended.
- GlobeNewswire
Esperion to Present at the BTIG Biotechnology Conference
ANN ARBOR, Mich., Aug. 06, 2019 -- Esperion (NASDAQ:ESPR) today announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology.
- GuruFocus.com
Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares
President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 5,000 shares of ESPR on 08/01/2019 at an average price of $39.56 a share. Continue reading...
- GuruFocus.com
Steven Cohen Charges Into Chiasma
Guru invests in clinical-stage biopharmaceutical company Continue reading...
- GlobeNewswire
Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
ANN ARBOR, Mich., July 30, 2019 -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial.
- Zacks
A Firm's First Profit Can Mean Big Returns for Investors
A Firm's First Profit Can Mean Big Returns for Investors
- TipRanks
3 Biotech Stocks Corporate Insiders are Buying
Biotech stocks can make compelling investments if investors can pick the right ones. One way to find these winners is to look at the stocks corporate insiders are buying. While an investment decision shouldn’t be made solely on the basis of insider activity, it is an important factor to consider. We are taking a closer look at 3 biotech stocks showing positive insider signals. AVROBIO, Inc. (AVRO)AVRO is a phase 2 clinical-stage gene therapy company that develops treatments for rare diseases such as Fabry Disease, a lysosomal disease that affects the kidneys, heart and skin. Following the announcement on July 19 that it closed its underwritten public offering of 7,475,000 shares of common stock, both the director, Bruce Booth, and Atlas Venture Fund X, L.P. bought over $15 million worth of the stock. Each bought 810,811 shares at an average price of $18.50 per share, with both becoming 24% owners. AVRO plans to use the money generated from the offering for its current Fabry Disease, Gaucher Disease, Cystinosis and Pompe Disease programs as well as to fund further research and development. The purchase comes after top analyst, Difei Yang, reiterated her Buy rating and $28 price target on July 16, suggesting 25% upside. The Mizuho Securities analyst said “AVROBIO has a $4.0 billion total addressable market (TAM). Available clinical data in Fabry disease has shown encouraging results with initial patients treated achieving meaningful improvements in enzyme activity levels and two patients discontinuing enzyme replacement therapy so far (the standard of care).”Another analyst, Debjit Chattopadhyay, also reiterated his Buy rating and $40 price target on July 16. He believes AVRO could soar by as much as 78% over the next twelve months. “While our price target reflects uncertainties stemming from the clinical update from the Fabry program (AVR-RD-01), resulting in: (1) a push out of our launch estimate into 2H-2022, vs. prior 2H-2021; and (2) lower Fabry POS of 25% from 30%, we believe the company is still poised for substantial long-term growth,” the H.C. Wainwright analyst said. The Street is also bullish on AVRO. The stock boasts a ‘Strong Buy’ analyst consensus and $34 average price target, indicating 51% upside potential.Esperion Therapeutics, Inc. (ESPR)ESPR specializes in developing lipid management treatments for patients with high cholesterol. On July 23, BIOTECH TARGET N V, bought 50,000 shares at an average price of $42.65 per share, bringing the total purchase price to over $2 million. This makes Biotech Target a 13% owner of the company.The buy comes after ESPR announced that it entered into a $200 million funding agreement with Oberland Capital on June 26. The agreement is based on net revenues from ESPR’s bempedoic acid and the bempedoic acid/ezetimibe combination tablet sales with $125 million given upfront, $25 million upon FDA approval and $50 million at Esperion’s option after launch.Cowen & Co. analyst, Chris Shibutani, argues that this funding will drive continued growth. On July 18, he maintained his Buy rating and $80 price target. He believes share prices could surge by as much as 92% over the next twelve months. On June 27, analyst, Michael Yee, said, “Esperion's debt financing brings in an immediate $125M, lifting the company's total pro-forma cash to $355M, and gives it flexibility going into 2020\. We view the deal as a non-dilutive, fundamentally good access to cash, that helps shore up Esperion's balance sheet in case of uncertainty and macro risk in 2020.” The Jefferies analyst maintained his Buy rating and $85 price target, suggesting 104% upside potential. ESPR has a ‘Moderate Buy’ analyst consensus, and $85 average price target, indicating 103% upside.Forty Seven, Inc. (FTSV)On July 22, both FTSV’s director, Jeffrey W. Bird, and Lightspeed Venture Partners X, L.P. increased their stakes in the cancer-fighting biotech company formerly known as CD47 Sciences, Inc. Bird purchased 750,000 shares for $6 million while Lightspeed bought 625,000 shares for $5 million at an average price of $8 per share.The purchase fell on the same day as the company’s announcement that it closed its public offering of 10,781,250 shares. The offering included 1,406,250 shares that could be bought by the underwriters. The buy also occurred shortly after news broke of its license agreement with Ono Pharmaceutical. On July 11, it was announced that FTSV would get the exclusive right to develop, manufacture and commercialize the 5F9 monoclonal antibody that targets CD47, a protein that can cause tumors. Analyst Swayampakula Ramakanth believes the licensing agreement could drive share price growth of 130% over the next twelve months. The H.C. Wainwright analyst maintained a Buy rating and $21 price target on July 12. “We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive rNPV of $1.1B for 5F9 and add in cash, cash equivalents, and short-term investments of $114M to arrive at a 12-month price target of $20.57 per diluted share, which we round to $21.00,” Ramakanth added. JonesTrading analyst, Soumit Roy, reiterated his Buy rating and $30 price target on June 14. He believes share prices could jump by an impressive 228% over the next twelve months. “We think share prices are going to recover following the success of the company’s anti-PD(L)-1 drugs,” he said. FTSV has a ‘Strong Buy’ analyst consensus and $26 average price target, suggesting 188% upside potential.
- GuruFocus.com
Weekly CEO Buys Highlight
Details the CEO buys this past week for the following companies: AXA Equitable Holdings, Liberty Latin America, Karuna Therapeutics, Esperion Therapeutics and Altus Midstream
- GlobeNewswire
Esperion and Oberland Capital Announce $200 Million Funding Agreement
Esperion (ESPR) and an investor group led by Oberland Capital Management LLC (Oberland Capital) today announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet were developed as complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) who require additional LDL-C lowering despite the use of currently accessible therapies. “We are very excited to collaborate with the team at Oberland Capital given their experience and expertise in the industry,” said Rick Bartram, chief financial officer of Esperion.
- Simply Wall St.
Have Insiders Been Buying Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares This Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- Zacks
Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
Esperion (ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to welcome Tracy to the Esperion board.
- Investor's Business Daily
Biotech Stocks Clobbered As Two Slammed With Sell Ratings
Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.
- GlobeNewswire
Esperion to Participate in Upcoming Investor Conferences
A live audio webcast of the Jefferies event can be accessed on the investor relations section of the Esperion website at www.esperion.com. Bempedoic acid is our lead, non-statin, complementary, orally available, once-daily, LDL-C lowering therapy. With a targeted mechanism of action, bempedoic acid is a first-in-class, ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers LDL-C by up-regulating the LDL receptor.
- MoneyShow
Esperion Aims for the First Approved Non-Statin Cholesterol Reducer
The FDA has accepted both New Drug Applications from Esperion (ESPR) for bempedoic acid and the bempedoic acid/ezetimibe combination tablet for filing and regulatory review, reports John McCamant, biotech specialist and editor of The Medical Technology Stock Letter.
